Posted in M&A / Deals Lilly exits Rigel alliance, adding to RIPK1 scrap heap April 22, 2026 BioSpace Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous sys M&A / DealsImmunology & InflammationRead full story